Researchers report an experimental drug that rewires rather than degrades prostate cancer's protein machinery, destroying testosterone receptors in lab studies.
Experimental drug retatrutide cut knee osteoarthritis pain by half for nearly 70% of patients across two clinical trials while also reducing body weight.